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Summary 
The application of price indices is useful to analyze the behavior of prices as an 
important component in patients´ access to essential medications over a period 
of time. The present work analyzed the variation in the prices of 303 medications 
sold by a cooperative of hospitals in central Colombia between 1999 and 2010 by 
applying inflation-adjusted price indices and Laspeyres-Paasche quantities by abc 
groups and principal therapeuticals in the first and second atc (anatomic, thera-
peutical, chemical) level, taking 1999 as the starting year. The medications of type A 
and B, as well as those belonging to the first four therapeutical groups in the first atc 
level in cost and for seven groups in the second atc level, registered a drop between 
40 and 53% (P < 0.05) in the applied price indices. In addition, all the abc and 
atc groups showed increases between 9 and 12 times (P < 0.01) when applying the 
indices on units sold. The estimated net saving in 2010 at prices of 1999, went above 
$ 16.9 billion cop. This impact on prices has helped to expand the coverage in essen-
tial medications supplied to the public hospitals which are afterwards administered 
to the patients of this region of Colombia.
Key words: Prices of medications, use of medications, pharmaceutical economics.
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Resumen
Impacto del grupo de compra en la cooperativa de hospital en 
Colombia, con un índice de precios de 1999 a 2012
La aplicación de los índices de precios es útil para analizar el comportamiento de los 
precios como un componente importante en el acceso de los pacientes a los medica-
mentos esenciales en un determinado período de tiempo. El presente trabajo analiza 
la variación de los precios de 303 medicamentos comercializados por una coopera-
tiva de hospitales en el centro de Colombia entre 1999 y 2010 mediante la aplicación 
de los índices de precios ajustados a la inflación, según las expresiones de Laspeyres y 
Paasche por grupos abc y de principales agentes terapéuticos en el primer y segundo 
nivel atc (anatómico, terapéutico, químico), tomando 1999 como año de partida. 
Los medicamentos de tipo A y B, así como los que pertenecen a los cuatro primeros 
grupos terapéuticos en el primer nivel de atc en el costo, y considerando siete 
grupos en el segundo nivel de atc, registraron una caída entre 40% y 53% (P < 0,05) 
en los índices de precios aplicados. Además, todos los grupos abc y atc mostraron 
aumentos entre 9 y 12 veces (P < 0,01) al aplicar los índices en las unidades vendidas. 
El ahorro neto estimado en 2010 a precios de 1999, pasó por encima de 16,9 mil 
millones de pesos colombianos. Este impacto en los precios ha contribuido a ampliar 
la cobertura en los medicamentos esenciales suministrados a los hospitales públicos, 
y que luego son administrados a los pacientes de esta región de Colombia.
Palabras clave: precios de los medicamentos, uso de medicamentos, economía farma-
céutica.
Introduction 
Price is a key determinant of patients’ access to essential medications. In low- and 
middle-income countries, large proportions of the population have limited access to 
medicines, either because of poor availability or because patients must pay for their 
prescriptions and are not able to do so [1]. In health care institutions in developing 
countries, expenditure on medications is second only to staffing costs [2]. Understand-
ing the trends and evolution of medication prices can help health care institutions pre-
dict their future expenditures and assist in making purchasing decisions. 
In most market transactions, the price and quantity sold tend to move inversely: As 
the price falls, the quantity sold increases, and vice versa. The relationship between 
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prices and quantities for medications is more complicated as there are a number of 
factors that influence the price of medications, including availability of substitute 
mediations or treatments, patent licenses expiration dates, and trends in treatment 
best practices [3]. 
Beginning in the 1980s, regional cooperatives of public hospitals in Colombia were 
developed in order to optimize the processes of purchase and supply of medications 
and medical devices [4]. One such cooperative was the Cooperative of Hospitals of 
the Departments of Caldas and Quindío (coodesca), founded in 1989 in the cof-
fee-growing triangle in central Colombia and encompassing over 40 public hospitals 
[5]. This region is consists by the departments of Caldas, Risaralda y Quindío with 
53 towns, 13,873 km2 (less than 2% of the total area of the country), and a estimated 
population of 2.5 million in 2010. The Gross Domestics Product of the region repre-
sents 4.1% of the national total [6].
As with other cooperative, a principle activity for coodesca was to purchase generic 
but essential medications for its members. coodesca used a regionally-focused 
pooled procurement model which has been found in other parts of the world to be 
effective in reducing drug prices [7-10]. Together to others eight hospital cooperatives 
in Colombia, coodesca forms aliancoop (Alliance of Colombian Cooperative 
of Hospitals), which gathers over 400 public hospitals in the country, to make joint 
purchases of medicines since 2000, except for 2003 by logistical failures. Although, 
eventually process has changed from one year to another, several steps have remained 
stable such as [11]:
Consolidation of medicines requirements of every cooperative of hospitals.1. 
Prepare and send tender documents.2. 
Invite suppliers to participate in the tender process.3. 
Evaluate suppliers for pre-qualification.4. 
Receive offers through a web platform.5. 
Open and evaluate offers for adjudication.6. 
Divulgate adjudication.7. 
Issue agreements to winner bidders.8. 
Monitor performance and quality of products.9. 
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All of the participant hospital cooperatives apply a homogenous quality assurance pro-
grams for medicines that distribute to associated hospitals. Quantity needs of medi-
cines are based on hospitals requirements.
To date, no study has examined the impact of these cooperatives and other develop-
ments on medication prices and quantities. The present study analyzes the behavior of 
the purchase costs (regarded as cost of annual average stock) and the amount of units 
sold by coodesca for principal medications according to cost by abc and therapeu-
tic groups according to the who atc classification, using weighted economic indices 
and aggregated indices of prices and quantities. Three index numbers (Laspeyres (L) of 
fixed weightings, Paasche indexes (P) of variable weightings, and Fisher index (F) that 
use arithmetic means of past indexes) are used to compare the evolution over time of 
the behavior of a variable or group of variables that are measured using different units. 
The objective of the study is therefore to describe the trend overtime in the cost and 
quantities of abc and atc classified mediations to examine the relationship between 
prices and the quantities of medications.
Methodology
Data: Yearly data on the prices and units distributed of medications from the Coop-
erative of Hospitals of Caldas and Quindío (coodesca) were obtained from its own 
information system. Unit prices come from the adjudication by joint procurement, and 
units were those distributed to hospitals associated to the Cooperative. The abc clas-
sification system corresponded to year 2012. For the atc classification system, there 
were four principal therapeutic groups (antiinfectives for systemic use ( J), blood and 
blood forming organs (B), nervous system (N) and cardiovascular (C)) and eight sec-
ond level groups: antibacterials for systemic use ( J01), blood substitutes and perfusion 
solutions (B05), sexual hormones and modulators of the genital system (G03), drugs 
for obstructive airway diseases (R03), analgesics (N02), agents acting on the renin-
angiotensin system (C09), antiepileptics (N03), and drugs for acid related disorders 
(A02). Those therapeutic groups were the most important in costs in 2012. 
Indexes: The dependent variables were indices of the cost of the annual average stock 
and the number of units of medications supplied. The costs are reported in Colombian 
pesos (cop) in 2012 (1 US$ = 1,798.23 cop) with 2012 as reference year using the 
annual customer price index (cpi) reported by the Colombian Department of Statis-
tics (dane) [12, 13] for the period under study (1999-2012). 
The reference period is December 2007, with the prices in each period being calculated 
in reference to their change, either positive or negative, from the respective year of 
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reference. Thus, prices in March of 08 were 12.2% above the reference period, while 
prices in June were 1.32% below. The same principles used for price indices are used 
for quantity indices. 
The Laspayres indexes that use the base period orientation, was applied for prices and 
quantities according the following formula [14-16]:
Laspeyres price index: 
IPL =
q p
q p
i0
0 0
∑
∑  
Laspeyres quantity index: 
ICL =
q p
q p
i 0∑
∑ 0 0  
Where q represents quantities and p represents prices; subindex 0 represents the refer-
ence period, while i represents the subsequent periods. The resulting indices mean of 
100 with each 1% percentage increase in the score representing a 1% increase in prices/
quantities relative to the baseline year (1999). 
Analysis: The results are presented separately for the abc and atc classifications. The 
study used abc (Pareto) analysis to examine the prices and quantities of consumption 
patterns over time [17]. Items were classified in three categories (A, B, and C) based 
on the value of the annual usage. Class A items are 20% of the items accounts for 70% 
of the annual consumption value of the items; class B items are 20-30% of the items 
accounts for 20-25% of the annual consumption value of the items, and class C items, 
the rest. Because Class A items make up the majority of the budget, it was expected 
that the price and quantity changes would be greater for these items than for the Class 
C Items Another way to categorize drug consumption is by therapeutics groups. The 
Anatomical Therapeutic Chemical (atc) classification system developed and main-
tained by the World Health Organization (who) a stable system of drug consump-
tion measurement, which can be used to follow and compare trends in the utilization 
of drugs within and across therapeutic groups [18]. In the Anatomical Therapeutic 
Chemical (atc) classification system, the active substances are divided into different 
groups according to the organ or system on which they act and their therapeutic, phar-
macological and chemical properties. Drugs are classified in groups at five different 
levels. The drugs are divided into fourteen main groups (1st level), with pharmacologi-
cal/therapeutic subgroups (2nd level). The others levels are related with chemical sub-
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groups. The analysis presents the Laspayres price and quantity weighted indexes (lpi and 
lqi). In order to examine the change over the period, the difference in prices between 
1999 and 2012 were calculated and multiplied by the number of units sold in 2012, 
only when in both years existed consumption. This provided an estimate of the cost 
savings or additional expenditure from the change in prices. Total costs and demanded 
units for the whole period were also analyzed to. Pearson correlation tests were used 
with a 0.05 level of significance employing the software STATGRAPHICS v5.1.
Results and discussion
Medications in 2012 
A total of 298 medications classified by therapeutic groups in the first atc level were 
taken into consideration, as shown in Table 1; 92.7% of the medications matched the 
current pos list (Compulsory Health Plan) of 2012 [19]. 
Table 1. Medications: atc classification 2012 and percentage of medications included in the pos 
list of 2012.
atc atc Class first level Medications(% of total)
pos Medications 
(% of each atc group)
A Alimentary tract and metabolism 30 (10.0) 27 (90.0)
B Blood and blood forming organs 21 (7.0) 20 (95.2)
C Cardiovascular system 38 (12.8) 36 (94.7)
D Dermatologicals 10 (3.4) 5 (50.0)
G Genito urinary system and sex hormones 15 (5.0) 15 (100.0)
H Systemic hormonal preparations, excluding sex 
hormones and insulins
10 (3.4) 10 (100.0)
J Antiinfectives of systemic use 49 (16.4) 49 (100.0)
L Antineoplastic and immunomodulating agents 1 (0.3) 1 (100.0)
M Musculo-skeletal system 13 (4.4) 11 (84.6)
N Nervous system 60 (20.1) 55 (91.7)
P Antiparasitic products, insecticides and 
repellents
13 (4.4) 12 (92.3)
R Respiratory system 28 (9.4) 25 (89.3)
S Sensory organs 8 (2.7) 8 (100.0)
V Various 2 (0.7) 2 (100.0)
Total 298 (100.0) 276 (92.6)
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The medications for the nervous system (N) accounted for 20.3% of the total, followed 
by antiinfectives of systemic use ( J) 16.3%, and cardiovascular (C) 13.0%. For G and J, 
all the medications were pos and cardiovascular accounted for 94.9%.
The medications in the second atc level showed that systemic antibacterials ( J01) 
accounted for 14.0% of the total, duplicating the second, psycholeptics (N05), which 
accounted for 6.0% (Table 2). All the medications of the first four groups with more 
drugs were part of the pos list.
Table 2. Medications: Second level of the atc classification 2012 and percentage of medications 
included in the pos list of 2012.
atc atc Class second level Medications(% of total)
pos Medications 
(% of each atc 
group)
J01 Antibacterials for systemic use 42 (14.0) 42 (100.0)
N05 Psycholeptics 18 (6.0) 18 (100.0)
R03 Drugs for obstructive airway diseases 14 (4.7) 14 (100.0)
B05 Blood substitutes and perfusion solutions 13 (4.3) 13 (100.0)
C01 Cardiac therapy 12 (4.0) 11 (91.7)
N01 Anesthetics 12 (4.0) 8 (66.7)
N02 Analgesics 11 (3.7) 11 (100.0)
G03 Sexual hormones and modulators of the genital system 11 (3.7) 11 (100.0)
N03 Antiepileptics 11 (3.7) 11 (100.0)
R06 Antihistamines for systemic use 8 (2.7) 8 (100.0)
C08 Calcium channel blockers 7 (2.3) 6 (85.7)
D08 Antiseptics and disinfectants 7 (2.3) 2 (28.6)
A03 Drugs for functional gastrointestinal disorders 7 (2.3) 7 (100.0)
S01 Ophtalmologicals 7 (2.3) 7 (100.0)
A02 Drugs for acid related disorders 6 (2.0) 6 (100.0)
C09 Agents acting on the renin-angiotensin system 5 (1.7) 5 (100.0)
Other 38 groups 109 (36.3) 98 (89.9)
Total 300 (100.0) 278 (92.7)
In the abc classification of costs of sale in 2012, the medications analyzed accounted 
for 89.7% of the total of medications sold by the cooperative in 2012 (Table 3). 
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Table 3. Distribution of number of medications analyzed in the total of the abc classification of 
costs of sale of coodesca in 2012.
abc 
Classification 
No. analyzed 
medications (%)
No. total medications 
in 2012
% Analyzed medications
of the total of 2012
A 80 (26.8) 88 90.9
B 90 (30.2) 111 81.1
C 128 (43.0) 416 30.8
Total 298 (100.0) 615 48.5
The highest percentage corresponded to type A medications (90.9%), followed by type 
B (81.1%), indicating that the medications compared had an important share in the 
costs of sale. When comparing again with cost (Table 4), type A medications accounted 
this time for the highest percentage and C accounted for the lowest percentage. The 
medications compared accounted for 94.4% of the costs of sale in 2012, confirming 
the importance of the medications used in the comparison in the costs of sale.
Table 4. Distribution per costs of sale in the abc classification of costs of sale of coodesca in 2012 
of the medications analyzed.
abc 
Classification 
of 2012
Cost (cop) of sale of 
analyzed medications 
(%)
Total costs (cop) of 
sale of
medications in 2012
% of the cost of the 
medications analyzed 
of the total in 2012
A 4,455,969,719 (77.0) 4,742,058,434 94.0
B 980,025,476 (16.9) 1,204,722,879 81.3
C 349,875,107 (6.0) 578,855,246 60.4
Total 5,785,870,303 (100.0) 6,525,636,559 88.7
Movement of price indices for abc classification 
The Laspeyres aggregated price index (lpi) is shown in Figure 1. 
In the price indexes, there were ups and downs from 1999 to 2002, with a noticeable 
peak in 2003 which matches with the year was not undertaken group purchase, but 
with a tendency to descent over the whole analyzed period. The decline in the type B 
items was larger than the others (near to 57 points), while C type showed less diminu-
tion (around 38 points). A type showed similar behaviour to all products especially 
after year 2003, proving strong influence of type A items.
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Figure 1. Laspeyres Price Index (lpi) from 1999 to 2012 aggregated by abc classification of 2012, 
prices adjusted taking 1999 as reference year.
In the Pearson correlation analysis in the years analyzed and the values for the lpi, a 
high correlation was found, statistically very significant (P < 0.001) in the total (R2 = 
86.98% and correlation coefficient = -0.94) and for the products type A (R2 = 91.43% 
and correlation coefficient = -0.95) and B (R2 = 89.03% and correlation coefficient = 
-0.95), while for type C (R2 = 67.16% and correlation coefficient = -0.83), the correla-
tion was lower but significant (P < 0.002).
Movement of quantity indices for abc classification 
When applying the same index, but with respect to the units distributed, the constant 
growth behavior that started in 2002 stopped in 2008, and returned smoothly in 2012 
(Figure 2). However, C registered a slight downward trend since 2008, classes A and 
B products grew in 2012 to reach an increase over 23 times compared to 1999, while 
type B increased 8.9 times and type C only 2.9 times. This is to say, the products that 
have the highest weight in the costs of sale did not decrease their number of units sold 
in 2012 compared to 2009. It is important to highlight the dramatic growth between 
2005 and 2008, caused specially by the growth in products type A. Although in 2003 
group purchase was not done, quantities indices were not affected in a notable way.
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Figure 2. Laspeyres Quantity Index (lqi) from 1999 to 2012 aggregated by abc classification of 
2012, prices adjusted taking 1999 as reference year.
Movement of price indices for atc classification 
Drugs of the four therapeutic groups analyzed in the first atc level represented 49.4% 
of the total costs of sale in 2012, and the nine groups in the second atc level repre-
sented 55.4%. From 1999 to 2012 Laspayres price index, showed a downward trend, 
especially since 2003 and then this trend slowed down since 2008 (Figure 3). Group 
C (Cardiovascular system) showed the clearest decline with more than 65 point, while 
group B (Blood and blood forming organs) lowered less, with a drop of 26 point since 
1999 (Figure 3).
The summarized data are shown in Annex 1. The four groups showed negative correla-
tion (P < 0.01) statistically different in all indices, confirming the downward trend. 
In the second atc level, a clear-cut downward trend was observed in all indices in 8 
out of the 9 groups, except for the group G03 (sexual hormones and modulators of the 
genital system) principally because of contraceptives (Figure 4). For this group, price 
indices started to climb since 2008 and in 2012 its price index grew dramatically reach-
ing a value of 153 points. The introduction in the pos list in 2008 of several deposit 
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injection contraceptives, that have been distinguished and distributed by brand names, 
has been the main reason of this price behavior. Once again, in all figures can be seen 
how in 2003 the tendency was abnormal because of the absence of doing group pur-
chase this year.
Figure 3. Laspeyres Price Index (lpi) from 1999 to 2012 aggregated by classification in the first atc 
level, prices adjusted taking 1999 as reference year. J: antiinfectives of systemic use; B: blood and 
blood forming organs; N: nervous system; C: cardiovascular.
At the far end, group C09 showed the lowest price indices, with a decrease of more 
than 72 points, followed by groups A10 and N02. A statistical significance decrease 
was found in eight groups for all price indices (P < 0.001), but a positive correlation in 
the G03 group (P = 0.0523, R2 = 21.87% and correlation coefficient = 0.53). 
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Figure 4. Laspeyres Price Index (lpi) from 1999 to 2012 aggregated by classification in the second 
atc level, prices adjusted taking 1999 as reference year. J01: antibacterials for systemic use; B05: 
blood substitutes and perfusion solutions; G03: sexual hormones and modulators of the genital sys-
tem; R03: drugs for obstructive airway diseases; N02: analgesics; C09: agents acting on the renin-
angiotensin system; N03: antiepileptics; and A02: drugs for acid related disorders.
Movement of quantity indices for atc classification 
When applying the indices to the number of units distributed, in the first atc levels, 
highly meaningful increases were found (P < 0.001) in the four groups analyzed (Fig-
ure 5), which demonstrates an evident increase in the number of units sold for the 
medications that are key to the costs of sale. 
The G03 group showed a decrease tendency in units since 2008, because there has 
been ocurred a gradual substitution of oral anovulatories (levonorgestrel + etinilestra-
diol) by deposit contraceptives (norethisterone enanthate + estradiol valerate), which 
affected the comparison of the number of units sold and the costs. Beside to group 
G03, groups N03 and C08 showed a slight drop in their indices in 2012 compared to 
2011 in the Laspeyres quantity index (Figure 6).
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Figure 5. Logarithm of the Laspeyres Quantity Index (lqi) from 1999 to 2012 aggregated by clas-
sification in the first atc level, prices adjusted taking 1999 as reference year. J: antiinfectives of 
systemic use; B: Blood and blood forming organs; N: nervous system; C: cardiovascular.
Figure 6. Logarithm of the Laspeyres Quantity Index (lqi) from 1999 to 2012 aggregated by classi-
fication in the second atc level, prices adjusted taking 1999 as reference year.
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Net savings between 1999 and 2012 
The calculation of the net saving of the difference of prices between 1999 and 2012 
(Colombian pesos, cop 2012) gave a result of $ 23,982,355,260 (cop 2012), which 
represents 4.1 times the value of the cost of sale in 2012 for the medications analyzed, 
covering 211 drugs.
Units and total costs between 1999 and 2012 
Units demanded showed a clear increased tendency in the whole analyzed period 
of time (Figure 7). Among 199 and 2003 the increase was slight; with a growth rate 
around 2.2 million of units per year. From 2002 to 2004 the growth rate was bigger, 
but it was stabilized in 2005 due to the formal start setting joint procurement process. 
Since 2006 to 2008 a strong increase was noted, with a rate growth of almost 15 mil-
lion units per year after the joint purchase process was consolidated, and then rose 
again from 2008 to 2012 around 5% per year (Figure 7). Going down the units, also 
down costs and vice versa until 2008, except for 2003 when there were no joint pur-
chases. But from 2009 despite increased units, total costs decreased (Figure 7). Regard-
less, the total lpi (Figure 4) showed only increased in 2003 when joint purchases were 
not performed, because in all other years, there was a clear tendency to decrease.
Figure 7. Units demanded and total costs from 1999 to 2012.
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The purpose of this study was to analyze how joint purchase affected unit price costs 
using a acknowledged price index through a period over 10 years for a Cooperative of 
public hospitals in a developing country.
The mission of the cooperatives of hospitals consists basically in attaining efficiency in 
the processes to supply medications and medical devices to its members. Medications 
have a remarkable share in this process. In this way, a concrete goal is to get the best 
purchase prices for quality products and, at the same time, improve the supply of the 
medications and medical devices. 
Throughout the 14-year period analyzed, coodesca was able to cut off the purchase 
prices valued via costs of annual average stock, by 45% (Laspeyres index), especially 
after 2003, when the cooperatives of hospitals started to optimize the process of annual 
group purchasing. One of this success factors has been the use of the international non-
proprietary names (inn) to acquisition during the last two decades, which has allowed 
the offer of multiple mean more competition for prices [20].
On the contrary, the quantity indices showed a noticeable growth depending on the 
index applied, but it was higher for type A medications and lower for type C. This 
means that while there was a drop in the prices of the medications that had a high 
weight in costs of sale, there was a simultaneous increase in the number of units sold, 
which was in favor of the financial situation of the hospitals members of the cooperative.
When the same analysis was applied for the main four atc therapeutic groups by costs 
of sales divided in groups, it was found that the groups C, N, R03, and J01 had a drop 
in the price indices; while for the groups J, B, and, in particular, B05 there was a smaller 
drop. The group G03 showed a slight upward trend in its prices. This situation could be 
related to the degree of monopolization on the part of the suppliers of the medications 
included in these groups. The group B05 is composed mainly by high volume liquids 
and the group G03 is composed by oral contraceptives; these two groups have been 
usually bought from the same suppliers, which has avoided their group purchasing (to 
obtain the best prices). These items have been bought via direct negotiation, generating 
a situation of monopoly, which is against the interests of the cooperative. This situation 
has not occurred for the other therapeutic groups, which has allowed obtaining better 
purchase prices throughout time. 
Even with the situation aforementioned, the growth in the index of quantities in the 
group G03 can be highlighted, which can be evidence that even with the current cir-
cumstances coodesca’s sale prices remain competitive and, therefore it was possible 
to expand the target market. This was more evident in the notorious increase in cardio-
vascular medications (C) and nervous system medications (N), which demonstrates the 
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positive impact of the drop in purchase prices. As the profits of a cooperative should be 
invested in itself, and because these companies are non-profit, the lowest price quotes 
allowed the purchase of higher amounts of products. 
In the case of cardiovascular (C) and anti-asthma (drugs for obstructive airway dis-
eases) it is important to highlight the decrease in prices and the simultaneous increase 
in quantities. In Colombia, disease burden of hypertensive diseases using the disabil-
ity-adjusted life year (daly) is first for men and second for women, while respira-
tory diseases are sixth for men and seventh for women [21]. According 2010 data, 
ischemic heart and cerebrovascular diseases mortality for people over 45 years old in 
Colombia (263.7 per 100,000 habitants), were higher than the Latin America and the 
Caribbean region (57.0 per 100,000 habitants) [22]. In the region of coodesca, the 
mortality rate of circulatory system diseases was superior to the country median in 
both Departments: 211.5/100,000 habitants in Caldas and, 185.5 in Quindío versus 
132.2/100,000 habitants in 2008 [22]. This behavior means a net benefit expressed by 
an increase in access to high demand medications at better prices. 
The stabilization since 2003 in the quantities of products of the groups J01 and B05 
could indicate that there was good coverage of these medications in the influence area 
of the cooperative. This situation is different for the groups mentioned above. 
Drug access has been an evident problem in Colombia’s health system. In 2005, only 
51.63% of patients received all medications prescribed [23]. The rest of them have to 
pay out of pocket the medications needed. Another independent analysis in 6 cities 
different than the Triangle of Coffee showed that access of drugs of the Compulsory 
Health Plan was 88.1% and 87.3% at public and private pharmacies, respectively. 
When the authors compared some price generic drugs with an international reference, 
Colombian drug prices were at least 3.2 times more expensive, and hydrochlorothi-
azide (a representative antihypertensive medicine) was 12.4 times more costly [24]. 
Additionally, drug cost for the health system has increased dramatically in the last years. 
Between 2009 and 2008, costs of medicines increased over 160% and in consumption 
around 27%, for the regimen of employees (contribution). Twenty ambulatory drugs 
expenditures increased 601% in the same period [25]. It means that Cooperatives of 
public hospitals through its activity of group purchase, decrease cost of drug favoring 
greater access, although the great part of sector in the health care system has serious 
problems with drug expenditures. Besides, it matches with some strategies proposed in 
the National Pharmaceutical Policy that promotes innovative logistic special programs 
and a properly offer of medicines to national health necessities [20]. 
The three methodologies of price indices with fixed and variable weighting showed a 
downward trend within the period analyzed. This trend was more noticeable in the 
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groups of medications type A and B within the abc classification of costs of sale, and 
simultaneously there was in increase in the quantity indices, also more noticeable in 
medications A and B. The same behavior was observed in the joint analysis of the 
principal atc therapeutic groups that are used to treat the highest morbidity impact 
pathologies in the region. 
Price variation and amount of medications sold throughout time is the consequence of 
the interaction between pharmaceutical policies to control prices and the influence of 
the pharmaceutical industry on the prescription and the epidemiology of the popula-
tion. This is the first analysis of medications prices evolution for a decade at the pub-
lic sector in Colombia using prices indexes and evidence is insufficiently described in 
the primary literature. Rovira et al. [26] applied the Laspeyres and Paasche indices to 
analyze the effect of diverse factors on the increase in prices of new anti-depressives 
and antipsychotics in the Catalán Health Service in Spain, and recommended the use 
of this methodology to study the behavior of prices and consumptions. Thomas and 
Schondelmeyer analyzed the changes in the prices of the medications consumed by 
the senior population using the Laspeyres index as an alternative to the application of 
the producer price index (ppi) and the consumer price index (cpi), and remarked the 
indices´ utility in the study of price trends [27]. 
Although impacts of pooled procurement are scarce in papers [28, 29], the authors 
believe these data will give information to support a national pharmaceutical policy in 
order to improve availability and affordability. 
Conclusions
Through the application of composite price index we found that pharmacological 
groups for the treatment of most important pathologies in health public (cardiovas-
cular and respiratory drugs) and impact in costs (Types A and B in abc classification) 
were the most reduced their cost of acquisition. This will improve access to essential 
generic drugs, thanks to the pooled procurement process for public hospitals that serve 
the population with greater health needs and fewer resources.
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